Within one week, another two provinces announced the time of "4 + 7" expansion

[industry trends of pharmaceutical network] on December 13, Jiangxi Medical Security Bureau and Jiangxi health and Health Commission jointly issued the notice on the implementation of the results of the pilot project of centralized drug purchase and use organized by the state to expand the regional scope, which was decided on December 20 From 0:00 on, all public medical and health institutions in the province will implement the "4 + 7" national expansion results, and primary medical and health institutions, including township hospitals, will implement the results of the selection before December 25, 2019 Coincidentally, on the same day, Zhejiang medical insurance bureau also released the implementation plan for Zhejiang Province to implement the pilot project of centralized drug purchase and use organized by the state to expand the regional scope, and implemented and deployed the work of "4 + 7" expansion In addition, it also explicitly encourages the voluntary participation of designated social medical institutions and designated retail pharmacies According to incomplete statistics, as of November 8, at least 19 provinces have issued formal implementation plans or drafts for comments on promoting the implementation of pilot expansion In addition, Hainan, Guangdong, Hunan, Jilin, Henan, Gansu, Anhui, Hubei, Jiangsu and other provinces and cities that have issued documents to determine the implementation time of the "4 + 7" expansion results have now announced that the areas officially implementing the "4 + 7" expansion have blossomed all over the country According to the results of pilot expansion and selection published by the state joint procurement office on September 30, the price of 25 selected drugs has decreased to different degrees compared with the pilot selection price, with an average decrease of 25%, and the effect of price reduction is obvious For patients, the benefits of "4 + 7" expansion are obvious While the policy promotes the reasonable return of drug prices, it can also save more medical insurance funds, patients can enjoy more high-quality and low-cost drugs, and the drug cost will decrease It is reported that 11 pilot cities have started to purchase in volume since April 1 According to the current pilot effect, patients with major diseases such as tumor, hepatitis B, hypertension and mental illness in the pilot area have enjoyed the preferential price reduction, and the burden of medical expenses has been greatly reduced In fact, the "4 + 7" expansion will not only squeeze out the high water content of drug price, benefit patients, but also have a profound impact on the entire pharmaceutical industry, forcing enterprises to adapt to the new market environment Industry insiders said that only with volume purchase, standardized drugs can be rapidly released The original research and first generic drugs will no longer enjoy the favorable dividend of policy, or even be replaced by better varieties of generic drugs The life cycle and dividend of a single variety will be greatly shortened, and only innovative drugs have more development potential In the past, most of Chinese pharmaceutical enterprises earned the difference by the mode of distribution and distribution Compared with transnational pharmaceutical enterprises, the proportion of R & D expenses of domestic pharmaceutical enterprises accounted for the business income But now, the R & D investment of domestic pharmaceutical companies is accelerating to catch up In the future, if drug companies want to have long-term competitiveness, they will continue to invest more in innovative drug research and development According to the national requirements, all localities will focus on the implementation of the results of the selection, and ensure that patients can use the high-quality and cheap varieties of the selection before the end of the year After the "4 + 7" procurement expansion, 25 provinces, including Anhui, Hubei and Hainan, will implement the new results and supporting policies in addition to the 11 pilot cities in the early stage By the end of the year, more provinces and cities will confirm the nodes of "4 + 7" expansion time In the face of the changing market situation, pharmaceutical enterprises should also make a positive response In addition to investing in innovative pharmaceutical market and strengthening the academic promotion ability of marketing team, it will also be necessary for future survival and development.